Neuren Pharmaceuticals Limited is a New Zealand-based company. The Company is a biopharmaceutical company focusing on the development of drugs for neurological disorders and cancer. In neurology, the drugs target both acute indications, such as traumatic brain injury and concussion, as well as chronic conditions, such as autism spectrum disorders and neurodegenerative diseases. In oncology, the focus is on developing monoclonal antibodies to treat breast and other cancers. The Company has three lead candidates, which include NNZ-2566 and Motiva in clinical development to treat a range of acute and chronic neurological conditions, and NNZ-2591 in preclinical development for chronic neurodegenerative conditions. The Company has operations in New Zealand and the United States.